Anticoagulation for Nonvalvular Diseases in Patients with a Limited Prognosis #461.
作者信息
Hilton Ryan, Hayes Micaela, Somers Emma, Brooten Justin, Gabbard Jennifer
出版信息
J Palliat Med. 2023 Aug;26(8):1147-1149. doi: 10.1089/jpm.2023.0083.
Abstract
摘要
相似文献
1
Anticoagulation for Nonvalvular Diseases in Patients with a Limited Prognosis #461.预后有限患者非瓣膜病的抗凝治疗#461
J Palliat Med. 2023 Aug;26(8):1147-1149. doi: 10.1089/jpm.2023.0083.
2
Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physicians.非瓣膜性心房颤动患者使用抗凝治疗的障碍：澳大利亚家庭医生的代表性调查
Stroke. 2008 Jan;39(1):227-30. doi: 10.1161/STROKEAHA.107.495036. Epub 2007 Nov 29.
3
Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.直接口服抗凝剂与维生素K拮抗剂在非瓣膜性心房颤动中的疗效和安全性比较：一项加拿大多中心观察性队列研究。
CMAJ Open. 2020 Dec 18;8(4):E877-E886. doi: 10.9778/cmajo.20200055. Print 2020 Oct-Dec.
4
Underutilization of anticoagulation therapy in chronic atrial fibrillation.慢性心房颤动中抗凝治疗的使用不足。
Jpn Heart J. 2001 Jan;42(1):55-65. doi: 10.1536/jhj.42.55.
5
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro.终末期肾病患者心房颤动管理中口服抗凝药的应用：专家共识
Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2079-2084. doi: 10.2215/CJN.02680316. Epub 2016 Oct 25.
6
Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials.非瓣膜性心房颤动的卒中预防：前瞻性随机试验综述
Ann Neurol. 1991 Oct;30(4):511-8. doi: 10.1002/ana.410300402.
7
Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study.非瓣膜性心房颤动门诊患者使用华法林：心房颤动抗凝与危险因素（ATRIA）研究
Ann Intern Med. 1999 Dec 21;131(12):927-34. doi: 10.7326/0003-4819-131-12-199912210-00004.
8
Cost-Effectiveness of Bridging Anticoagulation Among Patients with Nonvalvular Atrial Fibrillation.非瓣膜性心房颤动患者桥接抗凝的成本效益。
J Gen Intern Med. 2019 Apr;34(4):583-590. doi: 10.1007/s11606-018-4796-9. Epub 2019 Jan 8.
9
Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.直接口服抗凝剂与华法林在非瓣膜性心房颤动中的围手术期结局。
Circulation. 2018 Oct 2;138(14):1402-1411. doi: 10.1161/CIRCULATIONAHA.117.031457.
10
Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.心房颤动卒中后抗凝治疗的三个月风险效益概况：SAMURAI-非瓣膜性心房颤动（NVAF）研究
Int J Stroke. 2016 Jul;11(5):565-74. doi: 10.1177/1747493016632239. Epub 2016 Feb 29.
本文引用的文献
1
Trends in Use of Oral Anticoagulants in Older Adults With Newly Diagnosed Atrial Fibrillation, 2010-2020.2010-2020 年新诊断心房颤动老年患者口服抗凝药物使用趋势。
JAMA Netw Open. 2022 Nov 1;5(11):e2242964. doi: 10.1001/jamanetworkopen.2022.42964.
2
Use and Prescription of Direct Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation: A Multidisciplinary Consensus Document.老年和体弱房颤患者直接口服抗凝剂的使用与处方：多学科共识文件
J Pers Med. 2022 Mar 15;12(3):469. doi: 10.3390/jpm12030469.
3
Diagnostic Accuracy of the HAS-BLED Bleeding Score in VKA- or DOAC-Treated Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis.HAS-BLED出血评分在接受维生素K拮抗剂（VKA）或直接口服抗凝剂（DOAC）治疗的房颤患者中的诊断准确性：一项系统评价和荟萃分析
Front Cardiovasc Med. 2021 Nov 22;8:757087. doi: 10.3389/fcvm.2021.757087. eCollection 2021.
4
Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score.评估癌症相关血栓形成患者的出血风险：现有风险评分的评价及新风险评分的制定
Thromb Haemost. 2022 May;122(5):818-829. doi: 10.1055/s-0041-1735251. Epub 2021 Sep 20.
5
Use of antithrombotics at the end of life: an in-depth chart review study.生命终末期抗栓药物的应用：一项深入的图表回顾研究。
BMC Palliat Care. 2021 Jul 16;20(1):110. doi: 10.1186/s12904-021-00786-3.
6
Physicians' Opinions on Anticoagulant Therapy in Patients with a Limited Life Expectancy.医生对预期寿命有限的患者进行抗凝治疗的看法。
Semin Thromb Hemost. 2021 Sep;47(6):735-744. doi: 10.1055/s-0041-1725115. Epub 2021 May 10.
7
Anticoagulant Use for Atrial Fibrillation Among Persons With Advanced Dementia at the End of Life.终末期老年痴呆患者的房颤抗凝治疗。
JAMA Intern Med. 2021 Aug 1;181(8):1121-1123. doi: 10.1001/jamainternmed.2021.1819.
8
The risk of venous thromboembolism in cancer patients receiving chemotherapy: a meta-analysis with systematic review.接受化疗的癌症患者发生静脉血栓栓塞的风险：一项系统评价的荟萃分析。
Ann Transl Med. 2021 Feb;9(4):277. doi: 10.21037/atm-20-3292.
9
Use of Anticoagulants in Patients With Non-Valvular Atrial Fibrillation Who Are at Risk of Falls.抗凝剂在有跌倒风险的非瓣膜性心房颤动患者中的应用。
Cureus. 2020 Sep 9;12(9):e10336. doi: 10.7759/cureus.10336.
10
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.2020年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动诊断和管理指南：欧洲心脏病学会（ESC）心房颤动诊断和管理特别工作组，由ESC欧洲心律协会（EHRA）特别贡献制定。
Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.
Zotero 插件